Basilea Pharmaceutica Ltd. Logo

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX: BSLN). Through its fully integrated research and development operations the company focuses on the development of innovative antibiotics, antifungals and oncology drugs, targeting the medical challenge of resistance and non-response to current treatment options.

Thursday, July 30. 2015
Basel, Switzerland, July 30, 2015 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today topline results from the phase 3 ACTIVE study. The randomized double-blind study evaluated the efficacy and safety of intravenously (i.v.) and orally administered isavuconazole versus a regimen of i.v. caspofungin followed by oral voriconazole, as a potential treatment for adults with candidemia and other invasive Candida infections.
Friday, July 24. 2015
Basel, Switzerland, July 24, 2015 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion recommending the approval of isavuconazole for the treatment of adult patients with invasive aspergillosis and adult patients with mucormycosis for whom amphotericin B is inappropriate. Invasive aspergillosis and mucormycosis are life-threatening fungal infections predominantly occurring in cancer and other immuno­compromised patients. Isavuconazole will be marketed under the trade name of CRESEMBA® if approved in the European Union.
Thursday, June 25. 2015
Basel, Switzerland, June 25, 2015 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today the start of a clinical phase 1/2a study with an oral formulation of its anti-cancer drug candidate BAL101553. BAL101553 is a microtubule-destabilizing small molecule, acting as tumor checkpoint controller (TCC) as it promotes tumor cell death through activation of an important checkpoint in cell proliferation.
Monday, May 04. 2015
Basel, Switzerland, May 4, 2015 - Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today the start of a clinical phase 1 study with the orally administered investigational drug BAL3833/CCT3833 in patients with advanced solid tumors. BAL3833/CCT3833 is the lead compound of a series of small molecule panRAF inhibitors recently in-licensed by Basilea.

Infectious Diseases
Society of America